Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, NeuroEPO could become a meaningful new treatment option for Alzheimer’s disease, though it remains in the testing phase in most countries. The drug received approval from Cuba’s Ministry of Health in 2025 for treating mild-to-moderate Alzheimer’s disease, and clinical trials are currently underway to evaluate its effectiveness and safety in broader populations. This approval represents a significant milestone—NeuroEPO is an intranasal form of erythropoietin, a hormone-based compound, that works through multiple mechanisms to protect brain cells and potentially slow cognitive decline. The key question is not whether NeuroEPO works, but whether it will become widely available and prove effective enough to complement or compete with existing treatments.
Initial trial data from the ATHENEA randomized clinical trial shows promise, with the drug demonstrating the ability to reduce amyloid deposits in the brain and protect against cell death. However, approval in Cuba does not mean the drug is available in the United States, Europe, or most other countries—it needs to successfully complete Phase 3 clinical trials and gain regulatory approval from agencies like the FDA before it becomes a mainstream treatment option. For families facing Alzheimer’s, NeuroEPO represents something worth monitoring: a drug candidate with a novel mechanism of action and preliminary evidence of benefit, even if it’s not yet ready for widespread use. Understanding what makes NeuroEPO different from existing treatments, and what gaps remain in our knowledge, can help patients and caregivers make informed decisions about their care options.
Table of Contents
- What Is NeuroEPO and How Does It Designed to Protect the Alzheimer’s Brain?
- Current Clinical Trial Status and International Approval
- Safety Profile: What We Know About Side Effects and Tolerability
- How NeuroEPO Compares to Existing Alzheimer’s Treatments
- Limitations and Unanswered Questions About NeuroEPO
- Accessing NeuroEPO: Current Options and Practical Considerations
- The Future Outlook for NeuroEPO in Alzheimer’s Care
- Conclusion
What Is NeuroEPO and How Does It Designed to Protect the Alzheimer’s Brain?
NeuroEPO is an intranasal medication—meaning it’s delivered as a spray into the nasal passages rather than taken orally or by injection. The active ingredient is erythropoietin, a hormone that is naturally produced by the kidneys but has also been studied for decades as a potential neuroprotectant due to its ability to protect and support brain cells. The intranasal delivery method is designed to allow the drug to reach the brain more directly, bypassing some of the barriers that oral medications face. The drug works through multiple pathways simultaneously, which is one reason researchers believe it has potential. NeuroEPO decreases amyloid-beta deposits in the brain—the toxic protein clumps that are central to Alzheimer’s pathology. It also reduces apoptosis, the process of programmed cell death that accelerates cognitive decline in Alzheimer’s patients.
Additionally, NeuroEPO reduces inflammatory molecules in the brain, improves blood flow to brain tissue, and helps prevent the loss of synapses—the connections between neurons that are essential for memory and thinking. This multi-target approach is different from some newer Alzheimer’s drugs like aducanumab and lecanemab, which primarily focus on clearing amyloid. NeuroEPO’s broader mechanism of action may explain why it has shown promise in early trials. What makes NeuroEPO particularly interesting is that it addresses inflammation and cell death in addition to amyloid pathology. A patient with mild-to-moderate Alzheimer’s disease typically has damage occurring across multiple biological systems in the brain—not just amyloid accumulation, but also inflammation, oxidative stress, and neuronal loss. A drug that addresses several of these mechanisms simultaneously may be more effective than a single-target approach, though this remains to be proven in large-scale trials.
Current Clinical Trial Status and International Approval
NeuroEPO has already been approved by Cuba’s Ministry of Health as of 2025 for treating mild-to-moderate Alzheimer’s disease, making it the first country to formally approve this medication for this indication. However, approval in Cuba does not mean the drug is available in the United States or Europe—regulatory agencies in different countries have different standards and approval pathways. In the U.S., the FDA requires completion of Phase 3 trials before granting approval, and NeuroEPO is currently in this phase of testing. The drug is registered in the ClinicalTrials.gov database under identifier NCT07178678, and Phase 2 trials are actively recruiting participants with mild-to-moderate Alzheimer’s disease. Phase 2 trials are designed to assess both efficacy and safety in a moderate-sized patient population, typically ranging from 100 to 500 participants.
If Phase 2 trials show positive results, Phase 3 trials—which are larger and longer—will follow. Phase 3 is where regulators look for confirmation that the drug works better than placebo and that side effects are acceptable. This process typically takes several years. It’s important to understand that Cuba’s approval, while scientifically relevant, doesn’t automatically make NeuroEPO available to patients in other countries. Regulatory approval is country-specific, and each nation has its own review process and standards. The United States FDA, the European Medicines Agency, and other regulatory bodies will each conduct their own independent review if and when a company submits an application for approval.
Safety Profile: What We Know About Side Effects and Tolerability
One of the most encouraging aspects of NeuroEPO in early trials is its safety profile. The medication has been well-tolerated by patients who have received it, with no major safety concerns identified in the studies conducted to date. No serious adverse events have been reported in the trial data that is currently available. For families considering a new Alzheimer’s treatment, safety is often the primary concern, especially when an older person is already taking multiple medications for other conditions. The intranasal delivery method itself appears safe and practical. Unlike injections or intravenous infusions, patients can self-administer the nasal spray at home, which improves convenience and adherence.
However, intranasal medications do carry some minor side effects in general—occasional nasal irritation, nosebleed, or headache are possible. These are typically mild and temporary, but they’re worth considering. Additionally, while no serious side effects have been reported to date, it’s important to remember that we’re still in the early-to-middle stages of clinical testing. Rare side effects sometimes don’t become apparent until a drug has been given to tens of thousands of patients over many years. For patients with a history of nosebleeds, severe nasal congestion, or certain nasal conditions, an intranasal medication might not be ideal, and a doctor would need to assess whether NeuroEPO is appropriate. This is a limitation worth noting—no drug is universally suitable for all patients.
How NeuroEPO Compares to Existing Alzheimer’s Treatments
The Alzheimer’s treatment landscape has expanded significantly in recent years. Existing approved drugs include cholinesterase inhibitors like donepezil, which provide modest symptom improvement, and newer disease-modifying drugs like lecanemab and aducanumab, which target amyloid accumulation. Lecanemab (Leqembi) requires intravenous infusions every two weeks and carries a risk of amyloid-related imaging abnormalities (ARIA), a condition where the clearing of amyloid can cause brain microhemorrhages or microinfarcts in some patients. NeuroEPO takes a different approach. Rather than directly clearing amyloid, it works to protect brain cells and reduce inflammation while also addressing amyloid pathology. This multi-mechanism strategy could potentially be more effective than single-target drugs, but that remains unproven.
The intranasal delivery is also a practical advantage compared to intravenous infusions—patients wouldn’t need to visit a clinic every two weeks for an infusion. This could improve medication adherence and quality of life for patients and caregivers. One important tradeoff to consider: NeuroEPO is not yet available in most countries, whereas lecanemab and donepezil can be prescribed today. If a patient or family member is currently dealing with symptomatic Alzheimer’s disease, waiting for NeuroEPO to complete trials is not a practical option. Existing treatments, while imperfect, offer benefits available now. NeuroEPO is best viewed as a potential future addition to the treatment toolkit, not a replacement for available options.
Limitations and Unanswered Questions About NeuroEPO
Despite promising early data, significant gaps remain in our understanding of NeuroEPO’s effectiveness. The drug has been tested primarily in patients with mild-to-moderate Alzheimer’s disease, but we don’t yet know how well it works in people with very early disease or advanced Alzheimer’s. We also don’t have long-term data on whether benefits persist over years of treatment, or whether patients eventually develop tolerance to the drug. These are crucial questions that will be answered only through larger, longer clinical trials. Another limitation is the source of the approval data. While Cuba’s approval is based on scientific evidence, it’s worth noting that different countries have different regulatory standards. Some countries may approve drugs based on smaller or shorter trials than others.
We’ll need to see how independent regulatory agencies like the FDA evaluate the same data. Additionally, because NeuroEPO is still in trials, we don’t yet know the optimal dose, the best patient population (certain subtypes of Alzheimer’s may respond better than others), or how it interacts with other Alzheimer’s drugs. Some patients might benefit from combining NeuroEPO with an anti-amyloid drug like lecanemab, while for others, NeuroEPO alone might be sufficient. Cost is another practical limitation. Even after approval, we don’t know what NeuroEPO will cost. Newer Alzheimer’s drugs are expensive—lecanemab costs approximately $26,500 per year. If NeuroEPO is similarly priced, insurance coverage and out-of-pocket costs could be significant barriers for many families.
Accessing NeuroEPO: Current Options and Practical Considerations
Currently, NeuroEPO is only approved and available in Cuba. Patients in the United States and most other countries cannot legally obtain or use NeuroEPO outside of clinical trials. If you or a loved one is interested in participating in trials, the ClinicalTrials.gov website allows you to search for ongoing studies by location and condition.
Entering “NeuroEPO” and “Alzheimer’s disease” will show available trials near you, if any. For most patients, clinical trial participation is not practical or possible—trials have specific eligibility criteria, may be geographically distant, and may be full. If you’re seeking new treatment options for Alzheimer’s disease right now, focus on approved medications and interventions with existing evidence, such as lecanemab, donepezil, cognitive stimulation, and lifestyle modifications including exercise and cognitive activity.
The Future Outlook for NeuroEPO in Alzheimer’s Care
If NeuroEPO successfully completes Phase 3 trials and gains FDA approval, it could become available to U.S. patients within the next 2-4 years, depending on regulatory timelines. Approval would represent a meaningful expansion of the Alzheimer’s treatment toolkit. The drug’s multi-mechanism approach and intranasal delivery could make it an attractive option for patients who can’t tolerate or access intravenous infusions, or for whom existing drugs have been insufficient.
However, the field of Alzheimer’s treatment is moving quickly. Several other drugs are in trials, and it’s possible that other agents with better efficacy, tolerability, or convenience will emerge simultaneously with NeuroEPO. The treatment landscape five years from now may look quite different from today, with multiple options available for different patient populations and disease stages. NeuroEPO is one promising candidate, but not the only one being pursued.
Conclusion
NeuroEPO represents a genuinely promising avenue for Alzheimer’s treatment, with a novel mechanism of action, preliminary evidence of effectiveness, and an acceptable safety profile. Its approval in Cuba in 2025 validates the scientific rationale behind the drug, and ongoing clinical trials will determine whether it lives up to that promise in larger, more diverse populations. The intranasal delivery method and multi-target approach offer practical and biological advantages over some existing treatments.
However, NeuroEPO is not yet available outside of clinical trials in most countries, and it remains unproven at the Phase 3 level. For patients and families dealing with Alzheimer’s disease today, the focus should be on evidence-based treatments that are available now—discussing options with a neurologist or dementia specialist, participating in cognitive engagement activities, and managing other health conditions that affect brain health. NeuroEPO is worth monitoring and understanding, but it is not yet a treatment option for most patients. Clinical trial results over the next 1-3 years will determine whether this drug becomes a standard part of Alzheimer’s care.
You Might Also Like
- Could Personalized Brain Models Guide Alzheimer’s Treatment?
- Can Immune-Targeted Treatments Slow Alzheimer’s?
- How Alzheimer’s Care Promises Can Become Emotionally Complicated
Related reading
- what Patients Should Know About Combined Brain Disease Testing
- why Alzheimer’s Research Is Becoming More Personalized
- could Precision Medicine Change Dementia Care
- what Middle-Aged Adults Should Know About Dementia Warning Signs
- can Small Behavior Changes Signal Alzheimer’s Earlier Than Expected
For more on this topic, see Alzheimer’s Association — clinical trials.
